CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Pliant Therapeutics links early immune biomarker activation to clinical response in PLN-101095 trial

By Public Technologies
  • Pliant Therapeutics presented new PLN-101095 clinical biomarker analyses and preclinical data at the 2026 Society for Immunotherapy of Cancer annual meeting.
  • Early immune activation during Phase 1 monotherapy was associated with subsequent clinical response following pembrolizumab initiation.
  • Preclinical combination treatment improved anti-tumor activity and survival, supporting the ongoing clinical trial.
  • The FORTIFY Phase 1b expansion is enrolling patients with advanced solid tumors resistant to immune checkpoint inhibitors.
  • Enrollment covers non-small cell lung cancer, high tumor mutational burden tumors and clear cell renal cell carcinoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090830PRIMZONEFULLFEED9872919) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk